Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jason Aaron Freed, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Jason Freed and Daniel Costa.
Jason Freed
Connection Strength
0.476
Daniel Costa
  1. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol. 2016 06; 11(6):918-23.
    View in: PubMed
    Score: 0.163
  2. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015 Dec; 90(3):369-74.
    View in: PubMed
    Score: 0.160
  3. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer. 2015 Sep; 16(5):e105-9.
    View in: PubMed
    Score: 0.153
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.